Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

PURPOSE: To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. PATIENTS AND METHODS: Patients with pr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Adjei, Alex A., Mandrekar, Sumithra J., Dy, Grace K., Molina, Julian R., Adjei, Araba A., Gandara, David R., Ziegler, Katie L. Allen, Stella, Philip J., Rowland, Kendrith M., Schild, Steven E., Zinner, Ralph G.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815996/
https://ncbi.nlm.nih.gov/pubmed/19841321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.6406
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars